Chugai Pharmaceutical Co Ltd
TSE:4519
Intrinsic Value
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. [ Read More ]
The intrinsic value of one
Chugai Pharmaceutical Co Ltd
stock under the Base Case scenario is
4 228.64
JPY.
Compared to the current market price of 4 860 JPY,
Chugai Pharmaceutical Co Ltd
is
Overvalued by 13%.
Chugai Pharmaceutical Co Ltd's market capitalization is 8T JPY.
Chugai Pharmaceutical Co Ltd stock price is 4 860 JPY.
Chugai Pharmaceutical Co Ltd stock (4 228.64 JPY) is 13% less than its price (4860 JPY).
Chugai Pharmaceutical Co Ltd stock price (4860 JPY) is 2% less than its DCF Value (4 954.19 JPY). Open DCF Valuation
Chugai Pharmaceutical Co Ltd stock (3 503.09 JPY) is 28% less than its price (4860 JPY). Open Relative Valuation
Chugai Pharmaceutical Co Ltd has upside potential of 30% compared to the average analyst price target.
Open Wall St Estimates
Chugai Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 29% to 29%.
Chugai Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 23% to 21%.
Chugai Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 2% per year over the next 3 years.
Chugai Pharmaceutical Co Ltd's Revenue has dropped by 12% over the past 12 months.
Chugai Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 21%.
Chugai Pharmaceutical Co Ltd's Revenue has been growing by 12% per year for the last 3 years.
Chugai Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 29%.
Chugai Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Chugai Pharmaceutical Co Ltd has very high three-year average ROE (Return on Equity): 26%. The company is very efficient at transforming stockholders' equity into net income.
Chugai Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Chugai Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Chugai Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Chugai Pharmaceutical Co Ltd has very high three-year average ROIC (Return on Invested Capital): 35%. The company is very efficient at using invested capital to generate operating income.
Chugai Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.
Chugai Pharmaceutical Co Ltd's short-term assets (1T JPY) exceed its short-term liabilties (288B JPY).
Chugai Pharmaceutical Co Ltd's long-term assets (2T JPY) exceed its long-term liabilties (307B JPY).
Chugai Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (739B JPY) than debt (6B JPY).
Chugai Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 19.8.
Chugai Pharmaceutical Co Ltd earns more than enough operating income (444B JPY) to safely cover interest payments on its debt (81m JPY).
Valuation Backtest
Chugai Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Chugai Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Chugai Pharmaceutical Co Ltd
Balance Sheet Decomposition
Chugai Pharmaceutical Co Ltd
| Current Assets | 1.4T |
| Cash & Short-Term Investments | 739B |
| Receivables | 320.3B |
| Other Current Assets | 307.1B |
| Non-Current Assets | 566.1B |
| PP&E | 420.7B |
| Intangibles | 19.9B |
| Other Non-Current Assets | 125.6B |
| Current Liabilities | 288.2B |
| Accounts Payable | 112.5B |
| Accrued Liabilities | 75.4B |
| Other Current Liabilities | 100.3B |
| Non-Current Liabilities | 18.8B |
| Long-Term Debt | 6.5B |
| Other Non-Current Liabilities | 12.3B |
Earnings Waterfall
Chugai Pharmaceutical Co Ltd
|
Revenue
|
1.1T
JPY
|
|
Cost of Revenue
|
-413.3B
JPY
|
|
Gross Profit
|
698.1B
JPY
|
|
Operating Expenses
|
-253.8B
JPY
|
|
Operating Income
|
444.2B
JPY
|
|
Other Expenses
|
-118.8B
JPY
|
|
Net Income
|
325.5B
JPY
|
Free Cash Flow Analysis
Chugai Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Chugai Pharmaceutical Co Ltd's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Chugai Pharmaceutical Co Ltd's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Chugai Pharmaceutical Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Chugai Pharmaceutical Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Chugai Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Chugai Pharmaceutical Co Ltd
is 6 301.75 JPY
with a low forecast of 4 545 JPY and a high forecast of 7 780.5 JPY.
Shareholder Return
Price
Chugai Pharmaceutical Co Ltd
| Average Annual Return | 17.12% |
| Standard Deviation of Annual Returns | 44.61% |
| Max Drawdown | -25% |
| Market Capitalization | 8T JPY |
| Shares Outstanding | 1 645 559 436 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Chugai Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 7,664 full-time employees. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The firm is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The firm operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
Chugai Pharmaceutical Co Ltd
stock under the Base Case scenario is
4 228.64
JPY.
Compared to the current market price of 4 860 JPY,
Chugai Pharmaceutical Co Ltd
is
Overvalued by 13%.
You don't have any saved screeners yet
